Metabolic syndrome increased the risk of myocardial infarction in patients with less severe CAD (HR 2.36; 95% CI 1.001-5.57), but this was not significant after adjusting for diabetes.
Cohort (n=1,080)
Does the presence of metabolic syndrome increase the long-term risk of mortality and cardiovascular events in patients with varying severity of coronary artery disease?
Metabolic syndrome and significant CAD increase the risk of cardiovascular morbidity, but the effect of metabolic syndrome is largely driven by the presence of diabetes.
Hazard Ratio: 2.36 (95% CI 1.001–5.57)
Absolute Event Rate: 16.3% vs 7.1%
p-value: p=0.0497
OBJECTIVES: To assess the long-term risk of mortality and cardiovascular events, related to metabolic syndrome (MetS), in patients with less, or more severe coronary artery disease (CAD). METHODS: One thousand and eighty patients were divided in four groups, according to severity of CAD (1=less than 50% or nonsignificant stenoses; 2=greater or significant stenoses), and according to MetS (A=no; B=yes). Risk was evaluated with the Cox regression analysis. RESULTS: About 18.9% of patients had less and 81.1% more advanced CAD. MetS was present in 45.1% of the first, and in 52.9% of the second group. At baseline, patients with MetS, or significant stenoses, had less favorable medical, biochemical, and angiographic characteristics. During a follow-up of 12.6+/-3.4 years, group 1B had higher incidence (16.3 vs. 7.1%) and hazard ratio 2.36 (1.001-5.57; P=0.0497) of myocardial infarction than group 1A; group 2B had a higher incidence (19.0 vs. 11.7%) and hazard ratio 1.67 (1.18-2.37; P=0.0041) of stroke than group 2A. Groups 2A and 2B, as compared with groups 1A and 1B, had a higher incidence of myocardial infarction (39.1 vs. 7.1; 41.8 vs. 16.3%); group 2B had higher incidence of stroke than group 1B (19.0 vs. 9.8%). After adjustment for common risk factors, group 2B retained an elevated risk of stroke. After additional adjustment for diabetes, no event was significantly related to MetS. CONCLUSION: At baseline, coronary patients with MetS, or significant angiographic alterations, had more cardiovascular risk factors. During follow-up, both MetS and significant CAD increased the risk of cardiovascular morbidity but not of mortality.
Solymoss et al. (Fri,) conducted a cohort in Coronary artery disease and metabolic syndrome (n=1,080). Metabolic syndrome vs. No metabolic syndrome was evaluated on Myocardial infarction (in patients with less severe CAD) (HR 2.36, 95% CI 1.001-5.57, p=0.0497). Metabolic syndrome increased the risk of myocardial infarction in patients with less severe CAD (HR 2.36; 95% CI 1.001-5.57), but this was not significant after adjusting for diabetes.